What it's for (Indications)
- Trihexyphenidyl is indicated as an adjunct in the treatment of all forms of parkinsonism, including the postencephalitic, arteriosclerotic, and idiopathic types.
- It is particularly effective in alleviating the rigidity and reducing the salivation associated with Parkinson's disease, although its effect on tremor may be less pronounced.
- Additionally, trihexyphenidyl is widely used to control extrapyramidal disorders (e.
- g.
- , dystonia, akathisia, parkinsonism) induced by central nervous system drugs such as phenothiazines, thioxanthenes, and butyrophenones.
- Its primary role in drug-induced parkinsonism is to counteract the acetylcholine excess resulting from dopamine receptor blockade, thereby restoring a more balanced neurotransmitter state in the basal ganglia.
- Its use may significantly improve the quality of life for patients experiencing these debilitating movement disorders.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Dosage of trihexyphenidyl must be carefully individualized to achieve optimal therapeutic response while minimizing adverse effects. For idiopathic parkinsonism, treatment typically initiates with a small dose, such as 1 mg (0.5 mg in sensitive patients) on the first day, increasing by 2 mg increments every 3 to 5 days until an optimal maintenance dose is reached. The usual maintenance dose ranges from 6 to 10 mg daily, administered in 3 to 4 divided doses with meals. Some patients, particularly those with severe postencephalitic parkinsonism, may require higher doses, up to a maximum of 15 mg daily. For drug-induced extrapyramidal disorders, an initial dose of 1 mg is usually given, and the dosage is gradually increased until satisfactory control is achieved, typically ranging from 5 to 15 mg daily in divided doses. It is advisable to take the medication with or after meals to mitigate potential gastrointestinal irritation. Abrupt cessation should be avoided to prevent exacerbation of symptoms. |
Safety & Warnings
Common Side Effects
- Trihexyphenidyl, owing to its anticholinergic properties, can produce a range of side effects, primarily dose-dependent.
- Common adverse reactions include dry mouth, blurred vision, dizziness, nausea, nervousness, and constipation.
- More serious, albeit less frequent, central nervous system effects can encompass mental confusion, disorientation, hallucinations, impaired memory, agitation, and psychotic-like behavior, particularly in elderly patients or individuals with pre-existing cognitive impairment or psychiatric conditions.
- Cardiovascular effects may include tachycardia and palpitations.
- Genitourinary system effects can manifest as urinary retention or hesitancy, especially in patients with prostatic hypertrophy.
- Ophthalmic effects such as mydriasis, cycloplegia, and increased intraocular pressure are possible, which could precipitate acute narrow-angle glaucoma.
- Dermatological reactions like decreased sweating and rash may also occur.
- Patients should be monitored for these effects, and dosage adjustments or discontinuation may be necessary.
Serious Warnings
- Black Box Warning: Trihexyphenidyl does not carry a specific FDA Black Box Warning. However, it is imperative for healthcare professionals and patients to be fully aware of the *Serious Warnings* associated with its use, particularly regarding its potential for significant central nervous system effects. These include the precipitation of acute psychosis, severe hallucinations, confusion, and delirium, especially in elderly patients, those with pre-existing cognitive impairment, or individuals with underlying psychiatric conditions. There is a substantial risk of peripheral anticholinergic adverse effects, including acute urinary retention in patients with prostatic hypertrophy and the induction of acute angle-closure glaucoma in susceptible individuals, which can lead to vision loss. Furthermore, the drug's capacity to impair thermoregulation by decreasing sweating can result in life-threatening hyperthermia, particularly during exposure to hot weather or strenuous physical activity. Meticulous patient selection, careful dose titration, and continuous monitoring for these severe adverse reactions are essential to ensure patient safety and mitigate potential risks.
- Trihexyphenidyl should be used with extreme caution in patients with glaucoma, prostatic hypertrophy, obstructive disease of the gastrointestinal or genitourinary tracts (e.
- g.
- , pyloric or duodenal obstruction, achalasia, paralytic ileus), and in patients with cardiac, hepatic, or renal disease.
- Elderly patients are particularly vulnerable to central nervous system side effects such as confusion, disorientation, memory impairment, and hallucinations, necessitating careful titration and monitoring.
- Abrupt discontinuation of trihexyphenidyl can lead to an acute exacerbation of parkinsonian symptoms and, in rare instances, neuroleptic malignant syndrome-like symptoms if the drug was used to treat drug-induced parkinsonism.
- Decreased sweating and subsequent heat intolerance can occur, increasing the risk of hyperthermia, especially during hot weather or strenuous physical activity; patients should be advised to avoid overheating.
- Patients should be warned about the potential impairment of mental and/or physical abilities required for operating hazardous machinery or driving a motor vehicle, as sedation and blurred vision are common side effects.
- Regular ophthalmological examinations are recommended, especially for patients at risk of glaucoma.
How it Works (Mechanism of Action)
Trihexyphenidyl is a synthetic tertiary amine anticholinergic agent that functions primarily as a potent muscarinic acetylcholine receptor antagonist within the central nervous system. In Parkinson's disease, there is an imbalance between cholinergic and dopaminergic activity in the basal ganglia, characterized by a relative deficiency of dopamine and an overactivity of acetylcholine. Trihexyphenidyl acts by competitively blocking muscarinic M1 receptors, thereby reducing the excitatory cholinergic tone and helping to restore the neurotransmitter balance in the striatum. This action diminishes the characteristic symptoms of parkinsonism, such as rigidity and bradykinesia, and to a lesser extent, tremor. Its therapeutic effects are attributed predominantly to its central anticholinergic properties rather than its peripheral actions, although it does exert some direct antispasmodic effects on smooth muscle. The drug's ability to cross the blood-brain barrier is crucial for its antiparkinsonian efficacy.
Commercial Brands (Alternatives)
No other brands found for this formula.